by Mark Curtis | Jan 13, 2015
. Welcome to your Update from the Clinic for the month of December. bluebird bio’s first four patients are transfusion-free after treatment with its gene therapy Lentiglobin. Fate Therapeutics’ hematopoietic stem cell-modulating technology ProHema seems to be on track...
by Stacey Johnson | Jan 9, 2015
. Alzheimer’s disease is a chronic, neurodegenerative disease characterized by loss of memory and changes in behaviour in the early stage. It typically starts slowly and progresses, within a decade, to death from an external factor, such as an infection or pneumonia,...
by Stacey Johnson | Dec 12, 2014
. The Institute of Human Development, Child and Youth Health (IHDCYH), part of the Canadian Institutes of Health Research, is holding its IHDCYH Talks competition to feature research that falls within its mandate of improving knowledge translation and demonstrating...
by Mark Curtis | Dec 4, 2014
. The Edmonton Protocol for the transplantation of insulin producing cells into individuals with type 1 diabetes (T1DM) has a cost per quality-adjusted life year (QALY) of ~$165,000. This is more than three times the willingness-to-pay (WTP) in Canada, and comfortably...
by Stacey Johnson | Nov 28, 2014
. If you’ve never heard of epidermolysis bullosa (EB), you’re not alone. This rare genetic disease, which occurs in one of 20,000 births, creates fragile skin that tears at the slightest touch and results in blisters, sores and scar tissue. There is no cure. EB...
Comments